GO43860

Principal investigator

Dr. N. Steeghs

Medication

RO7502175 (anti-CCR8 antibody) + atezolizumab

• Expansion cohort A for melanoma PDL1+ – open
• Expansion Cohort A for PDL-1+ NSCLC – Closed
• Expansion cohort A for HNSCC – open
• Expansion cohort B for PDL1+ RCC – open
• Expansion cohort B for PDL-1+ NSCLC – open
• Expansion cohort B for melanoma (no PDL1 cutoff) – open
• Expansion cohort B for RCC (no PDL1 cutoff) – open
• Expansion cohort B CPI-experienced NSCLC – closed
• Expansion cohort B CPI-experienced HNSCC – closed
• CPI-naïve NSCLC cohort – open
• Expansion of serial biopsy cohort for all tumor types – open

Summary

This is a first-in-human study of the safety, tolerability, pharmacokinetics and anti-tumor activity of RO7502175 administered as monotherapy or in combination with atezolizumab in patients with advanced or metastatic solid tumors. Patients with NSCLC, HNSCC, melanoma, triple negative breast cancer, esophageal cancer, cervical carcinoma, urothelial cancer, renal cell carcinoma and hepatocellular carcinoma are eligible.

Read more on clinicaltrials.gov